12830 EL CAMINO REAL, SAN DIEGO, CA
Earnings Release
Acadia Pharmaceuticals Approves Amendment to 2024 Equity Incentive Plan
Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Annual Report to Security Holders
Board Appointment - Jonathan M. Poole Joins Acadia Pharmaceuticals Board
Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals Anticipates Over $1 Billion in 2025 Net Sales
Q2
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
S-3ASR
Definitive Proxy Statement
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload
S-8 POS